Propranolol

Generic Name: Propranolol

Brand Names: Hemangeol, Hemangiol, Inderal, Innopran

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁NO_₂

CAS Number: 525-66-6

Unique Ingredient Identifier: 9Y8NXQ24VQ

Background: Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.

Propranolol was granted FDA approval on 13 November 1967.

Indication: Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.

Associated Conditions: Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)

Associated Therapies: -

Clinical Trials

Propranolol for Diabetic Retinopathy

Phase 1

Completed

Conditions: Proliferative Diabetic Retinopathy

Interventions: Drug: Propranolol

First Posted Date: 2012-02-17

Last Posted Date: 2017-03-31

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 9

Registration Number: NCT01535495

Locations: 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States

Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)

Phase 4

Completed

Conditions: Graves´ Disease

Interventions: Drug: Diclofenac
Drug: Methimazole
Drug: Propranolol
Drug: L-thyroxin
Drug: Metoprolol

First Posted Date: 2011-10-25

Last Posted Date: 2016-02-24

Lead Sponsor: Mikael Lantz

Target Recruit Count: 65

Registration Number: NCT01458600

Locations: 🇸🇪
Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden
🇸🇪
Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden
🇸🇪
Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)

Phase 4

Conditions: Hepatocellular Carcinoma
Gastroesophageal Varices Hemorrhage

Interventions: Drug: propranolol

First Posted Date: 2011-10-14

Last Posted Date: 2019-09-04

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 100

Registration Number: NCT01451658

Locations: 🇨🇳
Veteran General Hospital-Taipei, Taipei, Ming-Chih Hou, MD, Taiwan

Reducing Reconsolidation of Trauma Memories With Propranolol

Phase 2

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Short acting + long acting propranolol + memory reactivation
Drug: Propranolol

First Posted Date: 2011-05-06

Last Posted Date: 2014-06-24

Lead Sponsor: Douglas Mental Health University Institute

Target Recruit Count: 76

Registration Number: NCT01349439

Locations: 🇨🇦
Douglas Mental Health University Institute, Verdun, Quebec, Canada

Controlling Hyperadrenergic Activity in Neurologic Injury

Phase 1

Withdrawn

Conditions: Dysautonomia
Traumatic Brain Injury

Interventions: Drug: Esmolol
Drug: Propranolol

First Posted Date: 2011-04-28

Last Posted Date: 2017-04-20

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01343329

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Reducing Drug Craving Memories

Not Applicable

Conditions: Cocaine Addiction

Interventions: Drug: Inderal

First Posted Date: 2011-03-21

Last Posted Date: 2011-05-19

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 60

Registration Number: NCT01319214

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Phase 1

Completed

Conditions: Invasive Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: Propranolol

First Posted Date: 2011-03-04

Last Posted Date: 2017-01-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 24

Registration Number: NCT01308944

Locations: 🇺🇸
Washington University in St. Louis, St Louis, Missouri, United States

Catecholamine Blockade Post-burn

Not Applicable

Conditions: Burns

Interventions: Drug: propranolol
Drug: placebo

First Posted Date: 2011-02-18

Last Posted Date: 2022-03-28

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 80

Registration Number: NCT01299753

Locations: 🇨🇦
Ross Tilley Burn Centre - Sunnybrook HSC, Toronto, Ontario, Canada

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol

Phase 4

Conditions: Liver Cirrhosis
Hepatoma

Interventions: Drug: propranolol

First Posted Date: 2011-02-17

Last Posted Date: 2011-06-15

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 60

Registration Number: NCT01298284

Locations: 🇨🇳
Veteran General Hospital-Taipei, Taipei city, Taiwan

A Randomized Trial of GVS Alone vs. Propranolol

Phase 4

Recruiting

Conditions: Bleeding Gastric Varices
Liver Cirrhosis

Interventions: Drug: propranolol

First Posted Date: 2011-02-17

Last Posted Date: 2019-09-04

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 120

Registration Number: NCT01298271

Locations: 🇨🇳
Veteran General Hospital-Taipei, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy